Multiple Myeloma: all 3,712 studies
Page 2 of 38. Open to participants first (752), then studies with results posted, then the rest; newest registration first within each.
- A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (R/RMM)RecruitingNCT07559799
- A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)RecruitingNCT07558915Phase 1
- Cognitive Impairment in Patients Undergoing Cell- and Antibody-based Immunotherapies for Haematological Malignancies: The COGNITOX StudyNot yet recruitingNCT07558057
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruitingNCT07555938Phase 3
- Benefits of a 6-month, Individualized, Hybrid, "Real-life" Adapted Physical Activity Program on the Quality of Life of Patients Treated for Multiple MyelomaRecruitingNCT07547007Not applicable
- Study of Thiotepa Combination With Melphalan (TM Protocol) Conditioning for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma：A Prospective Randomized Controlled Clinical TrialNot yet recruitingNCT07542418Not applicable
- Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory DiseaseRecruitingNCT07541391Phase 1
- A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.Not yet recruitingNCT07539233Early Phase 1
- BR101 in Patients With Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07537049Phase 1
- Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT07529782Phase 1
- Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic MalignanciesRecruitingNCT07523555Phase 1/2
- A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07518186Phase 3
- Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective StudyRecruitingNCT07514052
- Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07510100Phase 1/2
- IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell LeukemiaRecruitingNCT07509086Phase 2
- Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse EventEnrolling by invitationNCT07499128Not applicable
- Epunamin Combined With DECP for Relapsed/Refractory Multiple MyelomaRecruitingNCT07497165
- A Study of IMV102 in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT07493135Early Phase 1
- A Phase I Study of SHR-3836 in Patients With Multiple MyelomaRecruitingNCT07490613Phase 1
- Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal DysfunctionRecruitingNCT07489534Phase 2
- Identifying Effective and Cost-Conscious Maintenance Daratumumab DosingRecruitingNCT07485647Phase 2
- Multiple Myeloma t(4 ;14) FFPE SamplesNot yet recruitingNCT07482761
- Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple MyelomaRecruitingNCT07479979Phase 1/2
- Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple MyelomaRecruitingNCT07477912Phase 1/2
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Phase 1
- BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.Not yet recruitingNCT07474961Phase 4
- Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After TreatmentRecruitingNCT07463807Phase 1/2
- Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07458659Early Phase 1
- A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple MyelomaRecruitingNCT07455851Phase 1/2
- A Study of Elranatamab and Cyclophosphamide in People With Multiple MyelomaRecruitingNCT07454382Phase 2
- To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT07454187Phase 1/2
- A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07452198Phase 3
- One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMSRecruitingNCT07448935
- Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and TreatmentRecruitingNCT07448779
- FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor DiseaseRecruitingNCT07446777Not applicable
- Feasibility of a Multi-omics Platform for Hematological MalignanciesRecruitingNCT07445438Not applicable
- DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.RecruitingNCT07440290Phase 2/3
- A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.RecruitingNCT07429721Early Phase 1
- Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.Not yet recruitingNCT07421856Phase 1/2
- Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing RegimenRecruitingNCT07413809Phase 3
- Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid TumorsRecruitingNCT07410494Phase 1/2
- AI-Based Fine Morphological Subtyping of Myeloma Single Cells for Predicting FISH AbnormalitiesEnrolling by invitationNCT07410403
- MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple MyelomaRecruitingNCT07409454Phase 2
- A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)RecruitingNCT07409246Phase 1
- BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMMNot yet recruitingNCT07407010Phase 1
- INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)RecruitingNCT07403630Not applicable
- Validating Fish Oil's Role in Alleviating Bortezomib-Induced Neuropathy: A Multi-Method Study Integrating Big Data, Experimental, and Clinical ResearchNot yet recruitingNCT07403071
- A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male SubjectsNot yet recruitingNCT07400744Phase 1
- A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001）Not yet recruitingNCT07399444Early Phase 1
- A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)RecruitingNCT07393282Phase 3
- A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)RecruitingNCT07391657Phase 3
- Exercise Therapy for Multiple Myeloma PatientsNot yet recruitingNCT07388147Not applicable
- A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"RecruitingNCT07382739Phase 2
- DC/MM Fusion Vaccine With BCMA CAR-T in R/R MMRecruitingNCT07377435Phase 1
- Effects of Controlled Breathing on Cardiorespiratory Variables in Multiple MyelomaRecruitingNCT07376733Not applicable
- A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of TreatmentNot yet recruitingNCT07376720Not applicable
- Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple MyelomaRecruitingNCT07369895Phase 1
- Multiple Myeloma Extramedulary Disease Samples FFPENot yet recruitingNCT07354555
- Application Study of 68Ga-NOTA-BCMA Nanoantibody Imaging in Multiple MyelomaNot yet recruitingNCT07353554Not applicable
- A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)Not yet recruitingNCT07348393Phase 2
- CAR-T Immunomonitoring in Multiple Myeloma (CART I5M)RecruitingNCT07342179Not applicable
- Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null PhenotypeRecruitingNCT07341867Phase 1
- JY232(JY232) Injection in Relapsed/Refractory Multiple MyelomaRecruitingNCT07336823Early Phase 1
- A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple MyelomaRecruitingNCT07336472Phase 1/2
- Isa-VRD in TIE HRMMNot yet recruitingNCT07334535Phase 4
- Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple MyelomaRecruitingNCT07333430Phase 1
- IASO206 in Patients With Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07322159Early Phase 1
- 68Ga-BCMA PET/CT in Multiple MyelomaRecruitingNCT07319897Phase 2/3
- Effects of Controlled Breathing Added to Therapeutic Exercise in Multiple MyelomaRecruitingNCT07312942Not applicable
- A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT07312188Phase 2
- Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcomes in Older Patients (GA-ACT Trial)RecruitingNCT07309497
- Randomised Controlled Trial of Artificial Intelligence-assisted Health EducationRecruitingNCT07305337Not applicable
- A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantRecruitingNCT07297329Phase 3
- A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple MyelomaRecruitingNCT07294625Early Phase 1
- Halt Aging in Survivors of Blood CancersRecruitingNCT07292272Not applicable
- Survivors Uniting for Remote Guided ExerciseRecruitingNCT07290309Not applicable
- Patient-Reported Outcomes in Allogeneic Stem Cell Transplantation and CAR-T TherapyNot yet recruitingNCT07289087
- Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple MyelomaRecruitingNCT07285239Phase 3
- The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding AreasRecruitingNCT07285044Phase 2
- A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple MyelomaRecruitingNCT07284758Phase 2
- Anonymization of Clinical Data From Pseudonymized Databases Collected as Part of Previus Clinical Trials on Multiple MyelomaRecruitingNCT07283224
- A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma SubjectsRecruitingNCT07280013Phase 1
- Quality of Life Assessment of Caregivers of Patients With Multiple MyelomaNot yet recruitingNCT07276230Not applicable
- Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic MalignanciesRecruitingNCT07270263Not applicable
- Use of Preoperative Postbiotic Supplementation in Colorectal Cancer SurgeryRecruitingNCT07268846Not applicable
- A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07258511Phase 3
- A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic MalignanciesRecruitingNCT07255898Phase 1
- Effects of a Resistance Physical Exercise Program in Multiple Myeloma PatientsNot yet recruitingNCT07253103Not applicable
- A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell TherapyRecruitingNCT07249528
- CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple MyelomaRecruitingNCT07249073Early Phase 1
- Universal CAR-T Cell Therapy for MMRecruitingNCT07248176Not applicable
- ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple MyelomaNot yet recruitingNCT07247097Phase 2
- In VIVO CAR-T Therapy for Relapsed/Refractory Hematological MalignanciesRecruitingNCT07239323Phase 1
- Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple MyelomaRecruitingNCT07236502Not applicable
- e-Motion : Promoting Emotion Regulation in Chronic CancerRecruitingNCT07236021Not applicable
- SL4903 CAR-T Therapy for Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07234721Early Phase 1
- A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)RecruitingNCT07227311Phase 2
- An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic CancersRecruitingNCT07226934Not applicable
- A Dietary Study for People With Multiple MyelomaRecruitingNCT07226609Not applicable
- A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma PatientsRecruitingNCT07225738